Legend Biotech Corp (LEGN)

Currency in USD
15.99
-1.51(-8.63%)
Closed·
16.20+0.21(+1.31%)
·
Advertisement
Trading near 52-week Low
LEGN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
15.9717.50
52 wk Range
15.9737.50
Key Statistics
Prev. Close
15.99
Open
17.36
Day's Range
15.97-17.5
52 wk Range
15.97-37.5
Volume
2.83M
Average Volume (3m)
2.24M
1-Year Change
-46.1978%
Book Value / Share
6.57
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
LEGN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
40.93
Upside
+155.97%
Members' Sentiments
Bearish
Bullish
ProTips
Stock has taken a big hit over the last week

Legend Biotech Corp News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

8 Buy
6 Hold
0 Sell
Ratings:
14 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 40.93
(+155.97% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Evercore ISI
Hold---Downgrade13/11/2026
RBC Capital
Buy50.00+212.70%56.00Maintain11/11/2026
Morgan Stanley
Buy43.00+168.92%49.00Maintain11/11/2026
Oppenheimer
Hold25.00+56.35%40.00Maintain11/11/2026
H.C. Wainwright
Buy65.00+306.50%-Maintain11/11/2026

Legend Biotech Corp SWOT Analysis


Carvykti's Triumph
Legend Biotech's flagship product Carvykti drives remarkable 74.75% revenue growth, establishing itself as a leading treatment for multiple myeloma
Financial Fortitude
Explore Legend Biotech's robust liquidity position, with a current ratio of 4.71 and more cash than debt, despite negative EPS
Pipeline Potential
Delve into Legend Biotech's diverse pipeline, including promising CAR-T therapies for gastric, esophageal, and lung cancers, offering growth beyond Carvykti
Market Outlook
Analyst price targets range from $71 to $94, with an average of $82.20, reflecting confidence in Legend Biotech's growth prospects and pipeline potential
Read full SWOT analysis

Legend Biotech Corp Earnings Call Summary for Q2/2026

  • Legend Biotech posted Q2 adjusted EPS of $0.16 vs. $0.07 est., revenue of $387.5M vs. $362.8M est.; first profitable quarter company-wide.
  • CARVYKTI sales rose 50% YoY to ~$657M; U.S. sales up 32%, ex-U.S. up 128%; operating margin improved to 15% from negative 9% YoY.
  • Management expects adjusted net income profitability through H2 2026; gross margin to reach mid-50% in Q4, targeting 75% long-term.
  • Company plans U.S. IND filing for LB2501 in vivo CAR-T by end-2026; CEO search ongoing after leadership transition from Ying Huang.
  • Shares rose 5% premarket to $21.70; company holds $965M cash with no long-term debt, plans to settle ~$300M J&J loan in 2026.
Last Updated: 11/08/2026, 14:00
Read Full Transcript

Earnings

Latest Release
10/11/2026
EPS / Forecast
-0.13 / -0.00
Revenue / Forecast
359.5M / 358.63M
EPS Revisions
Last 90 days

Compare LEGN to Peers and Sector

Metrics to compare
LEGN
Peers
Sector
Relationship
P/E Ratio
−15,507.8x−1.3x−0.2x
PEG Ratio
-−0.040.00
Price/Book
2.4x2.6x2.6x
Price / LTM Sales
2.3x5.8x2.7x
Upside (Analyst Target)
148.2%633.5%66.0%
Fair Value Upside
Unlock24.2%10.8%Unlock

Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
42.23M21.77%675.31M
Other Institutional Investors
155.87M78.23%2.49B
Public Companies & Retail Investors
0.000.00%0.00
Total
198.1M100.00%3.17B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Genscript Biotech Corporation44.98%87,248,7781,395,108
FMR LLC12.32%23,905,228382,245

People Also Watch

335.35
LII
-4.74%
82.70
TXT
-1.14%
717.28
FICO
-0.40%
13.34
DLO
-2.56%
213.45
TEL
-1.34%

FAQ

What Is the Legend Biotech (NASDAQ: LEGN) Share Price Today?

The Legend Biotech stock price today is 15.99 USD.

What Stock Exchange Does Legend Biotech (LEGN) Trade On?

Legend Biotech is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for Legend Biotech?

The stock symbol (also called a 'ticker') for Legend Biotech is "LEGN."

What Is the Current Legend Biotech Market Capitalisation?

As of today, Legend Biotech (NASDAQ: LEGN) market cap is 3.10B USD.

What Is Legend Biotech's (LEGN) Earnings Per Share (TTM)?

The Legend Biotech EPS is currently -0.0011 (Trailing Twelve Months).

When Is the Next Legend Biotech Earnings Date?

Legend Biotech's next earnings report will be released on 16/03/2027.

Is LEGN a Buy or Sell From a Technical Analyst Perspective?

Based on today's Legend Biotech moving averages and other technical indicators, the daily buy/sell signal for LEGN stock is Strong Sell.

How Many Times Has Legend Biotech Stock Split?

Legend Biotech has split 0 times. (See the LEGN stock split history page for full effective split date and price information.)

How Many Employees Does Legend Biotech Have?

Legend Biotech has 3300 employees, based on their latest Companies House report.

What is the current trading status of Legend Biotech (NASDAQ: LEGN)?

As of 17/11/2026, Legend Biotech (LEGN) is trading at a share price of 15.99 USD, with a previous close of 15.99 USD. The stock has fluctuated within a day range of 15.97 USD to 17.50 USD, while its 52-week range spans from 15.97 USD to 37.50 USD.

What Is Legend Biotech (LEGN) Price Target According to Analysts?

The average 12-month price target for Legend Biotech is 40.93 USD, with a high estimate of 65 USD and a low estimate of 20 USD. 8 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +155.97% Upside potential.

What Is the LEGN Premarket Price?

LEGN's last pre-market stock price is 16.20 USD. The pre-market share volume is 10,640.00, and the stock has decreased by 0.21, or 1.31%.

What Is the LEGN After Hours Price?

LEGN's last after hours stock price is 16.00 USD, the stock has decreased by 0.01, or 0.06%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.